Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

PLoS Pathogens

Volumn 7, Issue 10, 2011, Pages

  Sashihara, Junji ^a   Hoshino, Yo ^a   Bowman, J Jason ^a   Krogmann, Tammy ^a   Burbelo, Peter D ^b   Coffield, V McNeil ^c   Kamrud, Kurt ^c   Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c AlphaVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3B; GLYCOPROTEIN 350; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; MEMBRANE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; LYMPHOCRYPTOVIRUS; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; RHESUS MONKEY; VACCINATION; VIRUS LIKE REPLICON PARTICLE; VIRUS LOAD; ANIMAL; BLOOD; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; HERPES VIRUS INFECTION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MACACA MULATTA; PATHOGENICITY; VIROLOGY; VIRUS INFECTION; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALIA; CERCOPITHECINE HERPESVIRUS 15; HUMAN HERPESVIRUS 4; LYMPHOCRYPTOVIRUS; MACACA MULATTA;

ANIMALS; DISEASE MODELS, ANIMAL; DNA, VIRAL; HERPESVIRIDAE INFECTIONS; HOST-PATHOGEN INTERACTIONS; LYMPHOCRYPTOVIRUS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; TUMOR VIRUS INFECTIONS; VIRAL LOAD; VIRAL VACCINES; VIRUS LATENCY; VIRUS REPLICATION;

EID: 80055066029     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002308     Document Type: Article

References (54)

1. North JR, Morgan AJ, Thompson JL, Epstein MA, (1982) Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A 79: 7504-7508.
2. Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK, (1985) Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318: 287-289.
3. Morgan AJ, Finerty S, Lovgren K, Scullion FT, Morein B, (1988) Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J Gen Virol 69: 2093-2096.
4. Morgan AJ, Allison AC, Finerty S, Scullion FT, Byars NE, et al. (1989) Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. J Med Virol 29: 74-78.
5. Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, et al. (1994) Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 12: 1180-1184.
6. Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, et al. (1992) Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J Gen Virol 73: 449-453.
7. Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ, (1993) Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol 74: 501-507.
8. Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, et al. (1988) Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 25: 189-195.
9. Gu SY, Huang TM, Ruan L, Miao YH, Lu H, et al. (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84: 171-177.
10. Moutschen M, Léonard P, Sokal EM, Smets F, Haumont M, (2007) Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25: 4697-4705.
11. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Léonard P, et al. (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196: 1749-1753.
12. Hislop AD, Taylor GS, Sauce D, Rickinson AB, (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
13. Gottschalk S, Heslop HE, Rooney CM, (2002) Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 84: 175-201.
14. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
15. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, et al. (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97: 835-843.
16. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, et al. (2008) Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82: 1448-1457.
17. Cadavid LF, Mejía BE, Watkins DI, (1999) MHC class I genes in a New World primate, the cotton-top tamarin (Saguinus oedipus), have evolved by an active process of loci turnover. Immunogenetics 49: 196-205.
18. Wang F, (2001) A new animal model for Epstein-Barr virus pathogenesis. Curr Top Microbiol Immunol 258: 201-219.
19. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, et al. (1997) An animal model for acute and persistent Epstein-Barr virus infection. Science 276: 2030-2033.
20. Habis A, Baskin G, Simpson L, Fortgang I, Murphey-Corb M, et al. (2000) Rhesus lymphocryptovirus infection during the progression of SAIDS and SAIDS-associated lymphoma in the rhesus macaque. AIDS Res Hum Retroviruses 16: 163-171.
21. Rivailler P, Jiang H, Cho YG, Quink C, Wang F, (2002) Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J Virol 76: 421-426.
22. Rangan SR, Martin LN, Bozelka BE, Wang N, Gormus BJ, (1986) Epstein-Barr virus-related herpesvirus from a rhesus monkey (Macaca mulatta) with malignant lymphoma. Int J Cancer 38: 425-432.
23. Cohen JI, Wang F, Kieff E, (1991) Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65: 2545-2554.
24. Cohen JI, Wang F, Mannick J, Kieff E, (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 86: 9558-9562.
25. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI, (2009) Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 391: 249-256.
26. Reed LJ, Muench H, (1983) A simple method of estimating fifty percent endpoints. Amer. J of Hygiene 27: 493-497.
27. Gedey R, Jin XL, Hinthong O, Shisler JL, (2006) Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 80: 8676-8685.
28. Yuen L, Moss B, (1987) Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A 84: 6417-6421.
29. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, et al. (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822-2830.
30. Jiang H, Cho YG, Wang F, (2000) Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus. J Virol 74: 5921-5932.
31. Rivailler P, Carville A, Kaur A, Rao P, Quink C, et al. (2004) Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood 104: 1482-1489.
32. Kamrud KI, Custer M, Dudek JM, Owens G, Alterson KD, et al. (2007) Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360: 376-387.
33. Kamrud KI, Alterson K, Custer M, Dudek J, Goodman C, et al. (2010) Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle. J Gen Virol 91: 1723-1727.
34. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, et al. (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239: 389-401.
35. Rao P, Jiang H, Wang F, (2000) Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein-Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections. J Clin Microbiol 38: 3219-3225.
36. Maruo S, Johannsen E, Illanes D, Cooper A, Zhao B, et al. (2005) Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical. J Virol 79: 10171-10179.
37. Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R, (2001) The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 29: 356: 475-488.
38. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, et al. (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176: 169-176.
39. Rickinson AB, Moss DJ, (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431.
40. Pearson G, Dewey F, Klein G, Henlé G, Henlé W, (1970) Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens induced by the virus. J. Natl. Cancer Inst 45: 989-995.
41. North JR, Morgan AJ, Epstein MA, (1980) Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int J Cancer 26: 231-240.
42. Thorley-Lawson DA, Poodry CA, (1982) Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 43: 730-736.
43. Khyatti M, Patel PC, Stefanescu I, Menezes J, (1991) Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. J Virol 65: 996-1001.
44. Epstein MA, Randle BJ, Finerty S, Kirkwood JK, (1986) Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin Exp Immunol 63: 485-490.
45. Emini EA, Schleif WA, Silberklang M, Lehman D, Ellis RW, (1989) Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge). J Med Virol 27: 120-123.
46. Rayner JO, Dryga SA, Kamrud KI, (2002) Alphavirus vectors and vaccination. Rev Med Virol 12: 279-296.
47. Khanna R, Sherritt M, Burrows SR, (1999) EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 162: 3063-3069.
48. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, et al. (2006) Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203: 995-1006.
49. Wallace LE, Wright J, Ulaeto DO, Morgan AJ, Rickinson AB, (1991) Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. J Virol 65: 3821-3828.
50. Gulley ML, Tang W, (2010) Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 23: 350-366.
51. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Haario H, et al. (2007) Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 45: 1305-1309.
52. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, et al. (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99: 4364-4369.
53. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, et al. (1995) Habermann TM, McGregor CG, Paya CV. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 20: 1346-1353.
54. Kersten MJ, Klein MR, Holwerda AM, Miedema F, van Oers, MH, (1997) Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest 99: 1525-1533.